Can a targeted pill plus chemo shrink lung tumors before surgery?

NCT ID NCT05430802

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus three cycles of cisplatin and pemetrexed, then undergo surgery. The study aims to see how many patients respond to this pre-surgery treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
furmonertinib combined with cisplatin and pemetrexed
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with EGFR-mutated lung cancer.
What could go wrong
This is an early-phase, single-arm trial with only 40 participants. It may not prove better than standard treatment, and the drug combination carries risks like chemotherapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tangdu Hospital

    RECRUITING

    Xi'an, Shannxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.